PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Abeona Therapeutics Inc. (ABEO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00289Y1073
CUSIP00289Y107
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$198.32M
EPS-$2.53
Revenue (TTM)$3.50M
Gross Profit (TTM)-$28.00M
EBITDA (TTM)-$45.91M
Year Range$2.73 - $9.01
Target Price$21.00
Short %6.55%
Short Ratio4.15

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ABEO

Abeona Therapeutics Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Abeona Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%1,000.00%2,000.00%3,000.00%4,000.00%NovemberDecember2024FebruaryMarchApril
-100.00%
3,863.95%
ABEO (Abeona Therapeutics Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Abeona Therapeutics Inc. had a return of 50.70% year-to-date (YTD) and 173.55% in the last 12 months. Over the past 10 years, Abeona Therapeutics Inc. had an annualized return of -35.33%, while the S&P 500 had an annualized return of 10.79%, indicating that Abeona Therapeutics Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date50.70%7.41%
1 month-8.26%-0.81%
6 months82.37%18.38%
1 year173.55%23.57%
5 years (annualized)-47.77%12.02%
10 years (annualized)-35.33%10.79%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-18.76%69.53%5.07%
2023-4.97%-9.26%25.65%4.37%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of ABEO is 90, placing it in the top 10% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of ABEO is 9090
Abeona Therapeutics Inc.(ABEO)
The Sharpe Ratio Rank of ABEO is 9393Sharpe Ratio Rank
The Sortino Ratio Rank of ABEO is 9090Sortino Ratio Rank
The Omega Ratio Rank of ABEO is 8787Omega Ratio Rank
The Calmar Ratio Rank of ABEO is 8989Calmar Ratio Rank
The Martin Ratio Rank of ABEO is 8989Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Abeona Therapeutics Inc. (ABEO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ABEO
Sharpe ratio
The chart of Sharpe ratio for ABEO, currently valued at 2.16, compared to the broader market-2.00-1.000.001.002.003.004.002.16
Sortino ratio
The chart of Sortino ratio for ABEO, currently valued at 2.93, compared to the broader market-4.00-2.000.002.004.006.002.93
Omega ratio
The chart of Omega ratio for ABEO, currently valued at 1.34, compared to the broader market0.501.001.501.34
Calmar ratio
The chart of Calmar ratio for ABEO, currently valued at 1.59, compared to the broader market0.001.002.003.004.005.006.001.59
Martin ratio
The chart of Martin ratio for ABEO, currently valued at 8.50, compared to the broader market0.0010.0020.0030.008.50
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.15, compared to the broader market-2.00-1.000.001.002.003.004.002.15
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.11, compared to the broader market-4.00-2.000.002.004.006.003.11
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.501.001.501.38
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.63, compared to the broader market0.001.002.003.004.005.006.001.63
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.76, compared to the broader market0.0010.0020.0030.008.76

Sharpe Ratio

The current Abeona Therapeutics Inc. Sharpe ratio is 2.16. A Sharpe ratio higher than 2.0 is considered very good.


Rolling 12-month Sharpe Ratio0.001.002.003.00NovemberDecember2024FebruaryMarchApril
2.16
2.15
ABEO (Abeona Therapeutics Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Abeona Therapeutics Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-100.00%
-2.49%
ABEO (Abeona Therapeutics Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Abeona Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Abeona Therapeutics Inc. was 100.00%, occurring on Feb 24, 2023. The portfolio has not yet recovered.

The current Abeona Therapeutics Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Jan 28, 19927620Feb 24, 2023
-88.54%Feb 18, 1988712Dec 12, 1990272Jan 13, 1992984
-39.84%Nov 3, 198723Dec 4, 198723Jan 8, 198846
-36.97%May 22, 198452Aug 7, 198413Aug 27, 198465
-28.38%Aug 31, 198412Sep 18, 19844Sep 24, 198416

Volatility

Volatility Chart

The current Abeona Therapeutics Inc. volatility is 27.71%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%NovemberDecember2024FebruaryMarchApril
27.71%
3.24%
ABEO (Abeona Therapeutics Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Abeona Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items